View more in
Cancer

Naratuximab Emtansine/Rituximab Combo Elicits Clinical Activity in Relapsed/Refractory DLBCL

onclive.com
 2021-06-12

The combination of naratuximab emtansine and rituximab yielded deep responses, and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma. The combination of naratuximab emtansine (Nara; Debio 1562, formerly IMGN529) and rituximab (Rituxan) yielded deep responses, and a duration of response...

www.onclive.com

Comments / 0

Comments / 0